Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours.
Dumez H, Awada A, Piccart M, Assadourian S, Semiond D, Guetens G, de Boeck G, Maes RA, de Bruijn EA, van Oosterom A. Dumez H, et al. Among authors: assadourian s. Ann Oncol. 2006 Jul;17(7):1158-65. doi: 10.1093/annonc/mdl071. Epub 2006 Apr 6. Ann Oncol. 2006. PMID: 16600980 Free article. Clinical Trial.
Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: results from the expansion cohort of a phase I study.
Khayat D, Tejpar S, Spano JP, Verslype C, Bloch J, Vandecaveye V, Assadourian S, Soussan-Lazard K, Cartot-Coton S, Van Cutsem E. Khayat D, et al. Among authors: assadourian s. Eur J Cancer. 2013 Mar;49(4):790-7. doi: 10.1016/j.ejca.2012.10.012. Epub 2013 Jan 10. Eur J Cancer. 2013. PMID: 23312881 Clinical Trial.
A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification.
Angevin E, Spitaleri G, Rodon J, Dotti K, Isambert N, Salvagni S, Moreno V, Assadourian S, Gomez C, Harnois M, Hollebecque A, Azaro A, Hervieu A, Rihawi K, De Marinis F. Angevin E, et al. Among authors: assadourian s. Eur J Cancer. 2017 Dec;87:131-139. doi: 10.1016/j.ejca.2017.10.016. Epub 2017 Nov 14. Eur J Cancer. 2017. PMID: 29145039 Free article. Clinical Trial.
Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.
Soepenberg O, Dumez H, Verweij J, Semiond D, deJonge MJ, Eskens FA, ter Steeg J, Selleslach J, Assadourian S, Sanderink GJ, Sparreboom A, van Oosterom AT. Soepenberg O, et al. Among authors: assadourian s. J Clin Oncol. 2005 Feb 1;23(4):889-98. doi: 10.1200/JCO.2005.01.008. J Clin Oncol. 2005. PMID: 15681535 Clinical Trial.
Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours.
Van Cutsem E, Khayat D, Verslype C, Billemont B, Tejpar S, Meric JB, Soussan-Lazard K, Assadourian S, Cartot-Cotton S, Rixe O. Van Cutsem E, et al. Among authors: assadourian s. Eur J Cancer. 2013 Jan;49(1):17-24. doi: 10.1016/j.ejca.2012.07.007. Epub 2012 Aug 24. Eur J Cancer. 2013. PMID: 22921183 Clinical Trial.
Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer.
Rougier P, Riess H, Manges R, Karasek P, Humblet Y, Barone C, Santoro A, Assadourian S, Hatteville L, Philip PA. Rougier P, et al. Among authors: assadourian s. Eur J Cancer. 2013 Aug;49(12):2633-42. doi: 10.1016/j.ejca.2013.04.002. Epub 2013 Apr 30. Eur J Cancer. 2013. PMID: 23642329 Clinical Trial.
Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours.
Freyer G, Isambert N, You B, Zanetta S, Falandry C, Favier L, Trillet-Lenoir V, Assadourian S, Soussan-Lazard K, Ziti-Ljajic S, Fumoleau P. Freyer G, et al. Among authors: assadourian s. Br J Cancer. 2012 Aug 7;107(4):598-603. doi: 10.1038/bjc.2012.304. Epub 2012 Jul 12. Br J Cancer. 2012. PMID: 22790797 Free PMC article. Clinical Trial.
A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Société Française d'Oncologie Pédiatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG).
Vassal G, Giammarile F, Brooks M, Geoerger B, Couanet D, Michon J, Stockdale E, Schell M, Geoffray A, Gentet JC, Pichon F, Rubie H, Cisar L, Assadourian S, Morland B. Vassal G, et al. Among authors: assadourian s. Eur J Cancer. 2008 Nov;44(16):2453-60. doi: 10.1016/j.ejca.2008.08.003. Epub 2008 Sep 21. Eur J Cancer. 2008. PMID: 18812255 Clinical Trial.
Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies.
Bahleda R, Baker J, Massard C, Gadgeel SM, Rogers JE, Izzedine H, Deutsch E, Garris JL, Khan A, Boelle E, Assadourian S, Soria JC, Ajani JA. Bahleda R, et al. Among authors: assadourian s. Oncology. 2016;90(1):10-20. doi: 10.1159/000440958. Epub 2015 Oct 23. Oncology. 2016. PMID: 26492090 Clinical Trial.
23 results